Biosimilar medical products – licensing, pharmacovigilance and interchangeability

Aleksandra Grozdanova; Katerina Ancevska Netkovska; Zoran Sterjev; Zorica Naumovska; Rubin Zarevski; Aleksandar Dimovski; Ljubica Suturkova

doi:10.1515/prilozi-2016-0006

.blurhash-client-img { display: none !important; }

Biosimilar medical products – licensing, pharmacovigilance and interchangeability

PRILOZI

Volume 37 (2016): Issue 1 (June 2016)

By: Aleksandra Grozdanova, Katerina Ancevska Netkovska, Zoran Sterjev, Zorica Naumovska, Rubin Zarevski, Aleksandar Dimovski and Ljubica Suturkova

Open Access

|Jul 2016

1. Dolinar RO, Reilly MS. The future of biological therapy: a pathway forward for biosimilars. GaBI Journal. 2013; 2(1): 36–40.
Open DOI Search in Google Scholar
2. Berkowitz SA, Engen JR, Mazzeo JR, Jones GB. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat Rev Drug Discov. 2012; 11 (7): 527–540.
Open DOI Search in Google Scholar
3. Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Giezen TJ, et al. Biosimilars: what clinicians should know. Blood 2012; 120 (26): 5111–5117.
Open DOI Search in Google Scholar
4. Fineberg SE, Kawabata TT, Finco-Kent D, Fountaine RJ, Finch GL, Krasner AS. Immunological responses to exogenous insulin. Endocr Rev. 2007; 28: 625–652.
Open DOI Search in Google Scholar
5. EMA/CHMP/437/04 Rev 1. Guideline on Similar Biological Medicinal Products. Available at:.
Search in Google Scholar
6. FDA. Information for Consumers (Biosimilars). Available at:.
Search in Google Scholar
7. WHO Expert Committee on Biological Standardization. Guidelines on evaluation of similar biotherapeutic products (SBPs). Available at:.
Search in Google Scholar
8. Health Canada. Fact Sheet: Subsequent Entry Biologics in Canada. Available at:.
Search in Google Scholar
9. Wang J, Chow SC. On the regulatory approval pathway of biosimilar products. Pharmaceuticals (Basel). 2012; 5(4): 353–368.
Open DOI Search in Google Scholar
10. EMA. Guideline on similar biological medicinal products. 2005. Available at:.
Search in Google Scholar
11. EMA. Guideline on Similar Biological Medicinal Products Containing Monoclonal Antibodies—Non-clinical and Clinical Issues. 2012. Available at:
Search in Google Scholar
12. EMA. Guideline on Immunogenicity Assessment of Monoclonal Antibodies Intended for In Vivo Clinical Use. 2012 Available at:
Search in Google Scholar
13. EMA. Guideline on Good Pharmacovigilance Practices. 2013 Available at:
Search in Google Scholar
14. Consensus Information Paper 2013. What you need to know about Biosimilar Medicinal Products. European Commission. Available at:.
Search in Google Scholar
15. McCamish M, Woollett G. Worldwide experience with biosimilar development. MAbs. 2011; 3: 209–217.
Open DOI Search in Google Scholar
16. EMA. Guideline on Similar Biological Medicinal Products. 2001. Available at:
Search in Google Scholar
17. Scott C. A decade of process development. BioProcess Int. 2012; 10: 72–78.
Search in Google Scholar
18. World Health Organization Executive Summary. Proceedings of the 55Consultation on International Nonproprietary Names for Pharmaceutical Substances, Geneva, 16-18 October 2012..
Search in Google Scholar
19. Silverman E. Biosimilars: what’s in a name? BMJ 2014; 348: g272
Open DOI Search in Google Scholar
20. Casadevall N, Edwards IR, Felix T, Graze PR, Litten JB, Strober BE, Warnock DG. Pharmacovigilance and biosimilars: considerations, needs, and challenges. Expert Opin Biol Ther 2013; 13: 1039–47.
Open DOI Search in Google Scholar
21. The Pharmaceuticals and Medical Devices Agency, Japan. March 2009 Guideline for the Quality, Safety, and Effectiveness of Biosimilar Products. Tokyo: Pharmaceuticals and Medical Devices Agency.
Search in Google Scholar
22. World Health Organization. Apr 2009. Guidelines on Evaluation of Similar Biotherapeutic Products. Geneva: World Health Organization Expert Committee on Biological Standardization.
Search in Google Scholar
23. World Health Organization. Jan 2014. Regulatory Expectations and Risk Assessment for Biotherapeutic Products: Scientific Principles to Consider.
Search in Google Scholar
24. European Generic Medicines Association. Biosimilars Handbook, 2nd ed. 2011, Brussels: European Generic Medicines Association.
Search in Google Scholar
25. Dörner T, Strand V, Castañeda-Hernández G, Ferraccioli G, Isaacs JD, Kvien TK, Martin-Mola E, Mittendorf T, Smolen JS, Burmester GR (2013) The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis. 72: 322–328.
Open DOI Search in Google Scholar
26. EMA. Questions and Answers on Biosimilar Medicines, 2012. Available from:.
Search in Google Scholar
27. Rovira, J, Espin J, Garcia L, Olry de Labry A. The Impact of Biosimilars’ Entry in the EU Market. Andalusian School of Public Health. 2011. Available at:.
Search in Google Scholar
28. Jelkmann W. Biosimilar epoetins and other “follow-on” biologics: update on the European experiences. Am J Hematol. 2010; 85: 771–780.
Open DOI Search in Google Scholar
29. France to allow biosimilars substitution. 2014. Available at:.
Search in Google Scholar
30. Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK. Biosimilars: the science of extrapolation. Blood. 2014; 124: 3191–3196.
Open DOI Search in Google Scholar

Authors

Metrics

Articles in this issue

DOI: https://doi.org/10.1515/prilozi-2016-0006 | Journal eISSN: 1857-8985 (formerly 0350-1914) | Journal ISSN: 1857-9345

Journal RSS Feed

Language: English

Page range: 27 - 36

Published on: Jul 15, 2016

Published by: Macedonian Academy of Sciences and Arts

In partnership with: Paradigm Publishing Services

Publication frequency: 3 issues per year

Keywords:

Related subjects:

© 2016 Aleksandra Grozdanova, Katerina Ancevska Netkovska, Zoran Sterjev, Zorica Naumovska, Rubin Zarevski, Aleksandar Dimovski, Ljubica Suturkova, published by Macedonian Academy of Sciences and Arts
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 37 (2016): Issue 1 (June 2016)